- Product
- Actinum is a troublemaker?
- by Kim JiEun Feb 7, 2022 05:57am
- Actinum is out of stock due to lack of inventory. The key is to return distribution inventory after the 11th. Multivitamin Actinum, which ambitiously entered Korea, is in a position to become a headache. It is not expected to be easy to order at pharmacies for the time being. According to an official at Dongwha Pharm on the 14th, Actinum'
- Product
- The gov is pushing to supply COVID-19 PO tx with pharmacies
- by Kang, Shin-Kook Jan 12, 2022 06:04am
- The government is taking full-fledged steps to supply COVID-19 PO treatment to pharmacies. The Central Disaster and Safety Counters Headquaters (CDSCHQ) will hold an online meeting this afternoon (10th) with drug organizations participating and discuss oral corona treatment prescriptions and dispensing. In other words, the direction of the CD
- Product
- Lee’s pledge to reimburse hair loss drug creates buzz
- by Jung, Heung-Jun Jan 6, 2022 06:09am
- The news that presidential candidate Lee Jae-Myung's is considering reimbursement of hair loss treatments as his election pledge is drawing attention for days. However, as many unresolved issues including creating empathy on its need, budgetary projections, and review of beneficiaries remain, it is unclear whether this may be practically
- Product
- Is the price of Paxlovid reasonable?
- by Jan 3, 2022 05:55am
- On the 27th, Paxlovid, an oral treatment for COVID-19, was approved for EUA by the MFDS, and the Pharmaceutical Association for Health Society asked questions about the insolvency and effectiveness of the screening process on the 30th. The Health Pharmaceutical Association said, "Paxlovid is expected to be used in patients with high risk amon
- Product
- Losartan's re-prescription & re-dispensing are imminent
- by Jung, Heung-Jun Dec 6, 2021 05:54am
- While the government's follow-up measures based on the results of Losartan impurity detection are expected to be announced this week, attention is being paid to the work guidelines for re-prescription and re-prevention. Items with problems with all manufacturing numbers are expected to be re-prescribed and re-manufactured, and items with prob
- Product
- Why Tagrisso and Opdivo failed reimbursement expansions
- by Moon, sung-ho Dec 6, 2021 05:53am
- The 3rd generation targeted therapy for lung cancer, ‘Tagrisso (osimertinib)’ once again failed to expand reimbursement to first-line treatment. The reason was that the drug was more appropriate as a second-line treatment in terms of cost-effectiveness. By failing to expand reimbursement at the last Cancer Drug Review Committee meeting held
- Product
- Organon aims to resume Cozaar XQ supply from 2022 Q1
- by Nov 25, 2021 05:56am
- 'Cozaar XQ,' an antihypertensive combination drug that contains losartan, may be resupplied to pharmacies within the first quarter of next year, at the earliest. The company had made preparations to change the API source of Cozaar XQ to be the same as the one for Cozaar, which uses a losartan API from a different overseas manufacturer (Fr
- Product
- α-GPC can't be replaced with other drugs in the field
- by Kim, Jin-Gu Nov 25, 2021 05:55am
- Apart from the steady increase in the number of patients over the past 20 years, there has been no significant change in dementia treatments used in Clinic sites. However, two major changes have been predicted in the past two years. One is the controversy over the preparation of Choline alfoscerate in Korea, and the other is the controversy surr
- Product
- AstraZeneca vaccination is expected to end as of this year
- by Nov 24, 2021 05:53am
- The first inoculation will end at the end of November, and for the second inoculation, all inoculations will end on the 31st of next month. Medical institutions that have AstraZeneca vaccines should provide primary vaccinations with vaccines they have, and inform the inoculated that secondary vaccinations should be cross-vaccinated with Pf
- Product
- Expansion of non-face-to-face tx little by little
- by Nov 18, 2021 05:54am
- Despite opposition from the KMA to expand non-face-to-face treatment using regulatory sandboxes, it is judged that the satisfaction of overseas Koreans is high and it will help resolve medical blind spots. However, concerns about allowing regulatory special cases are also expected to increase, taking advantage of regulatory sandboxes. Mini
